TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
NCT02180698 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it is completed. It studies TLR4 Agonist GLA-SE in Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma. The registry lists an enrollment of 16 participants at 1 site in 1 country. The registry lists a start date of 17 Nov 2014 and a primary completion date of 7 Oct 2016. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02180698 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Enrollment | 16 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma |
| Drugs | TLR4 Agonist GLA-SE |
| Start | 17 Nov 2014 |
| Primary completion | 7 Oct 2016 |
| Study completion | 7 Oct 2016 |
| Last update posted | 6 Nov 2019 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Seth Pollack
Fred Hutch/University of Washington Cancer Consortium
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fred Hutch/university of Washington Cancer Consortium
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02180698
Each answer restates registry values shown on this page.
What is NCT02180698?
NCT02180698 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies TLR4 Agonist GLA-SE in Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma.
Who leads NCT02180698?
The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.
Where does NCT02180698 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02180698 study?
The registered drug and biological interventions are TLR4 Agonist GLA-SE.
When did NCT02180698 end?
The registry lists a primary completion date of 7 Oct 2016 and a study completion date of 7 Oct 2016. The sponsor last updated the record on 6 Nov 2019.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.